Monthly Communication Report

Corporation:	AstraZeneca Canada Inc.
Associated registration:	957438-15042-66
Communication date:	2026-04-15
Posted date:	2026-05-15

Designated Public Office Holders who participated in the communication:	Shalene Curtis-Micallef, Deputy Minister Deputy Minister's Office, Health Canada (HC) Elizabeth  Wong, Senior Policy Advisor Office of the President of the Treasury Board of Canada, Treasury Board Of Canada Secretariat (TBS) Maggie Chi, Member of Parliament House of Commons Jocelyne Voisin, Senior Assistant Deputy Minister Health Policy Branch, Health Canada (HC) Annahat Kochar, Policy Advisor Treasury Board Of Canada Secretariat (TBS) Mackenzy Metcalfe, Policy Advisor Office of the Minister of Finance, Finance Canada (FIN) Nasser Haidar, Senior Policy Advisor Office of the Min. responsible for Canada-U.S. Trade, Intergovernmental Affairs and One Canadian Economy, Intergovernmental Affairs Secretariat (IGA) Footnote1 Justine Frame, Policy Advisor Minister's Office, Health Canada (HC) Sandenga Yeba, Director of Policy & Deputy Chief of Staff Office of the Minister of Health, Health Canada (HC) Pamela Aung-Thin, Assistant Deputy Minister Health Canada (HC) Ritu Banerjee, Assistant Deputy Minister Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
List of Details Subject matter Detail Health, Industry, Research and Development Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Economic Development, Federal-Provincial Relations, Health, Industry, Intellectual Property, Research and Development Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Budget, Economic Development, Federal-Provincial Relations, Foreign Affairs, Government Procurement, Health, Industry, International Trade, Research and Development Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Responsible Officer who filed this communication report:	Gaby Bourbara
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
Footnote1  Indicates new information that was added through a monthly communications return.